Recent advances in the pathophysiology and treatment of plasma cell dyscrasias

Key Points

• Enhanced understanding of the pathophysiology reveals key biomarkers for plasma cell dyscrasias.
• Novel interventions and therapies are being developed to target specific aspects of these conditions.
• Assessment of outcomes highlights promising efficacy of immunotherapy in recent clinical trials.
• Continued exploration is needed to bridge existing gaps in treatment and optimize care for affected patients.